Can a single shot of a genetically weakened malaria parasite train the body to fight off the real thing?

NCT ID NCT07730177

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Sanaria Inc. Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This trial tests a new malaria vaccine, PfSPZ-LARC2, made from live but genetically weakened malaria parasites that stop developing in the liver and never reach the bloodstream. The goal is to see if a single dose can safely and effectively protect healthy adults in Burkina Faso from malaria when they are later exposed to the parasite under controlled conditions. The vaccine is designed to trigger a strong immune response without causing actual malaria illness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a genetically weakened malaria vaccine called PfSPZ-LARC2, given as a single injection
What this could lead to
If successful, this could pave the way for a single-dose vaccine that provides strong, lasting protection against malaria.
What could go wrong
This is an early phase 1 trial with only 45 participants, so safety and efficacy are not yet established. The vaccine is genetically modified, and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA (PLASMODIUM FALCIPARUM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Groupe de Recherche Action en Santé (GRAS)/Unité de Recherche Clinique de Sabou

    Ouagadougou, 06, Burkina Faso

More trials for these conditions

Other studies related to the condition(s) this trial covers.